


Pironetin

| | | | |
|--------------------|--|-------|----------|
| Cat. No.: | HY-116446 | | |
| CAS No.: | 151519-02-7 | | |
| Molecular Formula: | C ₁₉ H ₃₂ O ₄ | | |
| Molecular Weight: | 324.45 | | |
| Target: | Microtubule/Tubulin | | |
| Pathway: | Cell Cycle/DNA Damage; Cytoskeleton | | |
| Storage: | Pure form | -20°C | 3 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



BIOLOGICAL ACTIVITY

| | | | |
|-------------------------------------|--|---|--|
| Description | Pironetin is an α/β unsaturated lactone isolated from <i>Streptomyces</i> species. Pironetin binds to α -tubulin and is a potent inhibitor of microtubule polymerization, and has cell cycle arrest and antitumor activity ^{[1][2]} . | | |
| IC₅₀ & Target | Microtubule ^[1] | | |
| In Vitro | Pironetin (20-100 ng/mL; 24 hours; 3Y1 cells) treatment arrests the cell cycle progression at G2/M in 3Y1 cells ^[1] . | | |
| | Pironetin (1-10000 ng/mL; 3 days; HeLa, A2780 and K-NRK cells) treatment inhibits the cell proliferation. IC ₅₀ values against these cell lines are almost 10 ng/mL ^[1] . | | |
| | MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | |
| | Cell Cycle Analysis ^[1] | | |
| | Cell Line: | 3Y1 cells | |
| | Concentration: | 20 ng/mL, 50 ng/mL, 100 ng/mL | |
| | Incubation Time: | 24 hours | |
| | Result: | Arrested the cell cycle progression at G2/M in 3Y1 cells. | |
| | Cell Proliferation Assay ^[1] | | |
| | Cell Line: | HeLa, A2780 and K-NRK cells | |
| Concentration: | 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL and 10000 ng/mL | | |
| Incubation Time: | 3 days | | |
| Result: | Inhibited the cell proliferation. | | |
| In Vivo | Pironetin (0.78-6.25 mg/kg; intraperitoneal injection; daily; for 5 days; female CDF1-SLC mice) treatment shows a moderate antitumor effect, however, a severe weight loss is observed as a side effect ^[1] . | | |
| | MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | |

| | |
|-----------------|---|
| Animal Model: | Female CDF1-SLC mice (10 weeks) injected with P388 murine leukemia cells ^[1] |
| Dosage: | 0.78 mg/kg, 1.56 mg/kg, 3.13 mg/kg, 6.25 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 5 days |
| Result: | Showed a moderate antitumor effect. |

REFERENCES

[1]. Kondoh M, et al. Cell cycle arrest and antitumor activity of pironetin and its derivatives. Cancer Lett. 1998 Apr 10;126(1):29-32.

[2]. Yang J, et al. Pironetin reacts covalently with cysteine-316 of α -tubulin to destabilize microtubule.] Nat Commun. 2016 Jun 30;7:12103.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA